Focused On-demand Library for Phospholipase A2 group V

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

PLA2-10; Phosphatidylcholine 2-acylhydrolase 5

Alternative UPACC:

P39877; Q8N435


Phospholipase A2 group V (PLA2G5), also known as PLA2-10 and Phosphatidylcholine 2-acylhydrolase 5, plays a pivotal role in lipid metabolism and immune response. It targets extracellular phospholipids, releasing fatty acids that influence macrophage polarization and contribute to lipid remodeling of cellular membranes. Its activities extend to promoting phagocytosis and exhibiting bactericidal action against Gram-positive bacteria, alongside roles in the biosynthesis of cysteinyl leukotrienes and regulation of IL33 production in pulmonary macrophages.

Therapeutic significance:

PLA2G5's involvement in Fleck retina, familial benign, underscores its potential in understanding retinal diseases. Its broad biological functions suggest that targeting PLA2G5 could offer novel therapeutic strategies for managing immune and inflammatory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.